ROCKVILLE, Md.--(BUSINESS WIRE)--March 22, 2007--Emergent
BioSolutions Inc. (NYSE: EBS) announced today the promotion of a
number of key executives to positions of expanded responsibility to
support the company's global business development strategies and
"I am very pleased to announce today's senior management
promotions," said Fuad El-Hibri, chairman and chief executive officer
of Emergent BioSolutions Inc. "These promotions mark an important step
in our continuing growth plans, and I am confident that the industry
expertise, commitment to success and leadership skills of these
executives will contribute greatly to the strategic and global
development of our company."
Specifics of the management changes, which will become effective
on April 1, 2007, include:
Daniel J. Abdun-Nabi is being promoted to president of
Emergent BioSolutions, overseeing a majority of the company's
corporate functions. Mr. Abdun-Nabi was formerly senior vice
president and general counsel for the company.
Robert G. Kramer, Sr., is being promoted to executive vice
president manufacturing operations, with responsibility for
global manufacturing, reporting directly to Edward J. Arcuri,
Ph.D., the company's chief operating officer. Mr. Kramer will
also continue as president of Emergent Biodefense Operations
Denise Esposito is being promoted to senior vice president and
general counsel. Ms. Esposito was formerly vice president and
deputy general counsel for the company.
Mauro Gibellini is being promoted to senior vice president
corporate development. Mr. Gibellini was formerly vice
president corporate development for the company.
In addition, the company announced that Steven N. Chatfield will
be joining the Health Protection Agency (HPA) in the UK in the Fall of
2007. Dr. Chatfield, who will remain with Emergent BioSolutions on a
full time basis through August 2007, has held dual roles as chief
scientific officer and president, Emergent Product Development UK,
since June 2004. The company is recruiting for a new chief scientific
"It is with regret that I leave Emergent BioSolutions but it is a
great privilege to be offered the opportunity to join the HPA, an
organization that is central to protecting the public health in the
UK," said Dr. Steven N. Chatfield. "I have spent my career developing
products and strategies to improve public health and this will give me
the opportunity to continue my work in the context of public health
protection in the UK. I have had an incredibly rich set of experiences
during my tenure at Emergent BioSolutions and have benefited immensely
from my time working with Fuad and the entire management team. I look
forward to spending the next few months ensuring a smooth transition
and will be leaving the company with the utmost confidence in its
continued development success."
"Steve Chatfield's contributions to our company's success have
been substantial," Mr. El-Hibri said. "Under Steve's leadership,
significant strides have been made in the development of our
commercial product portfolio. He has built a seasoned team of highly
skilled professionals with both management and product development
expertise. We look forward to working with Steve over the coming
months to ensure a smooth transition and wish him continued success
upon joining HPA later this year."
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused
on the development, manufacture and commercialization of
immunobiotics, consisting of vaccines and therapeutics that induce or
assist the body's immune system to prevent or treat disease. The
company's biodefense business is focused on immunobiotics for use
against biological agents that are potential weapons of bioterrorism.
The company's commercial business is focused on development,
manufacture and commercialization of immunobiotics for use against
infectious diseases. These immunobiotics are designed to address
significant unmet or underserved public health needs. More information
on the company is available at www.emergentbiosolutions.com.
Safe Harbor Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, our strategy,
future operations, future financial position, future revenues,
projected costs, prospects, plans and objectives of management and any
other statements containing the words "believes", "expects",
"anticipates", "plans", "estimates" and similar expressions are
forward-looking statements. There are a number of important factors
that could cause the company's actual results to differ materially
from those indicated by such forward-looking statements, including our
performance under existing BioThrax(R) sales contracts with the U.S.
government, including the timing of deliveries under these contracts;
our ability to obtain new BioThrax sales contracts with the U.S.
government; our plans for future sales of BioThrax; our plans to
pursue label expansions and improvements for BioThrax; our plans to
expand our manufacturing facilities and capabilities; the rate and
degree of market acceptance and clinical utility of our products; our
ongoing and planned development programs, preclinical studies and
clinical trials; our ability to identify and acquire or in license
products and product candidates that satisfy our selection criteria;
the potential benefits of our existing collaboration agreements and
our ability to enter into selective additional collaboration
arrangements; the timing of and our ability to obtain and maintain
regulatory approvals for our product candidates; our
commercialization, marketing and manufacturing capabilities and
strategy; our intellectual property portfolio; our estimates regarding
expenses, future revenue, capital requirements and needs for
additional financing; and other factors identified in the company's
Registration Statement on Form S-1 and subsequent reports filed with
the SEC. The company disclaims any intention or obligation to update
any forward-looking statements as a result of developments occurring
after the date of this press release.
CONTACT: Emergent BioSolutions Inc.
Robert G. Burrows, 301-795-1877
Vice President, Corporate Communications
SOURCE: Emergent BioSolutions Inc.